VivoSense Raises $25 Million to Collect Wearable Data for Clinical Drug Trials

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

VivoSense Raises $25 Million to Collect Wearable Data for Clinical Drug Trials
Image courtesy of VivoSense

As the CEO of Sarepta Therapeutics from 2011 to 2015, Chris Garabedian led a biotech firm striving to find cures for rare diseases. But because such diseases usually affect only a small population, it became difficult to collect a robust dataset on patients during clinical trials—the lengthy and rigorous process by which drugs are able to receive Food and Drug Administration approval for safety and efficacy.


At the time, Garabedian wanted to see if Sarepta could collect more data on its trial patients through the use of wearable sensors—but in 2011, as he recalled to dot.LA, it was hard to find technology that could collect and organize that kind of information.

More than a decade later, as the portfolio manager of an early-stage biotech investment fund, Garabedian is backing a company that’s looking to do just that.

VivoSense, a Newport Beach-based biometric data company, announced on Wednesday that it has raised $25 million in Series A funding co-led by Garabedian’s Perceptive Xontogeny Venture Fund and the Debiopharm Innovation Fund, the corporate venture arm of Swiss biopharma company Debiopharm. The new funding takes VivoSense to a total of $27 million raised to date..

VivoSense CEO Dudley Tabakin.

Photo courtesy of VivoSense

The startup collects and organizes data from biometric sensors that are used during clinical trials. The sensors track data like heart rate, breathing and bone density as participants use a drug, and provide valuable information to help understand how a drug affects a patient’s day-to-day life.

“There was a need to analyze that data and start using it to develop outcome measures that could be used in clinical trials by pharmaceutical companies,” VivoSense co-founder and CEO Dudley Tabakin told dot.LA.

The Series A funding will go towards building out VivoSense’s data technology for clinical trials, as well as for physicians who rely on remote monitoring technology to track patients who cannot visit the doctor as frequently.

“Pharmaceutical companies and biotechs should be proactively thinking about incorporating these types of methods into their clinical trials,” Garabedian told dot.LA. “It could make the difference between an approved drug or not.”

In 2020, the FDA revised its clinical trial standards after the pandemic kept people from leaving their homes, opening the door to a slew of companies tackling every aspect of a remote and distributed clinical trial system that still needs to be painstakingly accurate. El Segundo-based Lightship raised $40 million in September to create a fully-integrated virtual clinical trial setting, while Culver City-based Science 37 has received backing from large pharma companies like Thousand Oaks-based Amgen to make it easier for clinical trial conductors to find patients in a socially distant world.

The FDA’s move opened the door for more diversity in clinical trials, which is needed to accurately evaluate the safety of drugs. The agency has also been pushing for companies to collect more lifestyle data that “are meaningful to the patient”—like how they will react to a drug based on their sleep schedule, diet and health—rather than strict biologics, Tabakin said.
https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

LA-Based Apex Is Tapping Into the Small Satellite Market by Making Buses for Spacecraft

Spencer Rascoff

Spencer Rascoff serves as executive chairman of dot.LA. He is an entrepreneur and company leader who co-founded Zillow, Hotwire, dot.LA, Pacaso and Supernova, and who served as Zillow's CEO for a decade. During Spencer's time as CEO, Zillow won dozens of "best places to work" awards as it grew to over 4,500 employees, $3 billion in revenue, and $10 billion in market capitalization. Prior to Zillow, Spencer co-founded and was VP Corporate Development of Hotwire, which was sold to Expedia for $685 million in 2003. Through his startup studio and venture capital firm, 75 & Sunny, Spencer is an active angel investor in over 100 companies and is incubating several more.

​Ian Cinnamon
Ian Cinnamon

On this episode of Office Hours, Apex founder and CEO Ian Cinnamon discusses the importance of investing in space exploration and shares his thoughts on the evolving space ecosystem in Los Angeles.


Read moreShow less
https://twitter.com/spencerrascoff
https://www.linkedin.com/in/spencerrascoff/
admin@dot.la

This Week in ‘Raises’: Measurabl Snags $93M, Selva Ventures Grabs $34M

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

Raises
Image by Joshua Letona

A local data management platform company lands fresh funding to help commercial real estate owners reduce carbon footprint, while one Los Angeles-based venture firm closes its second fund to accelerate the growth of emerging companies across health, wellness, beauty and personal care.

***

Read moreShow less

McKinsey & Company Launches InLA Accelerator To Help Underrepresented Founders Tackle Startup Challenges

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

McKinsey & Company Launches InLA Accelerator To Help Underrepresented Founders Tackle Startup Challenges
InLA

In 2022, female founders saw a 28% decline in overall U.S. funding, while Black-led startups saw a 38% decline in total capital received. In an effort to increase funding for minority-led startups, global venture firm McKinsey & Company is launching InLA, an accelerator program for underrepresented founders.

“This effort is something that the firm has been really excited about for a long time,” Engagement Manager Elkhyn Rivas Rodriguez said. “There's obviously a meaningful and growing startup community out here and just from a diversity standpoint, LA is incredibly diverse and multi-ethnic and multicultural. So we think that there will be a really great pool of potential companies to partner with.”

Read moreShow less
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending